Psoriatic Arthritis

• HLA-B27 and genetic susceptibility: While only 60–70% of PsA patients are HLA-B27 positive (compared to >90% in ankylosing spondylitis), HLA-B27 remains the strongest genetic risk factor. The proposed mechanism involves molecular mimicry, where pathogenic microorganisms share epitopes with HLA-B27, activating autoreactive CD8+ T cells. Additionally, HLA-B27 may misfold during endoplasmic reticulum stress, forming homodimers that trigger innate immune responses through TLR3 and IL-23 pathway activation. Other HLA associations (HLA-B39, HLA-Cw6) contribute to disease susceptibility and phenotypic variation.

• IL-23 and Th17 cell differentiation: IL-23, a key driver in PsA pathogenesis, is produced by dendritic cells and innate lymphoid cells in response to microbial or autoantigens. IL-23 promotes differentiation of naive CD4+ T cells into Th17 cells, which produce IL-17A and IL-17F. These cytokines directly activate synovial fibroblasts, osteoclasts, and endothelial cells, triggering production of TNF-α, IL-6, and GM-CSF, perpetuating chronic synovial inflammation. IL-23 signaling also promotes Th1 cell differentiation and maintains pathogenic memory T cell responses. This explains why IL-23 inhibitors (e.g., guselkumab, risankizumab) and IL-17 inhibitors (e.g., secukinumab, ixekizumab) have become cornerstone therapies.

• TNF-α and synovial inflammation: TNF-α is elevated in synovial fluid and serum of PsA patients and serves as a critical amplification signal for joint destruction. TNF-α stimulates synovial fibroblasts to produce matrix metalloproteinases (MMPs), particularly MMP-1, MMP-3, and MMP-9, which degrade cartilage extracellular matrix and type II collagen. TNF-α also activates osteoclasts through RANKL upregulation, leading to periarticular bone erosion and juxta-articular osteopenia. The rapid clinical response to TNF inhibitors (infliximab, adalimumab, etanercept) underscores TNF's central role in disease pathogenesis.

• Dysbiotic microbiota and molecular mimicry: Dysbiosis of the gut microbiota, characterized by increased Faecalibacterium prausnitzii and altered barrier function, has been documented in PsA. Intestinal dysbiosis permits microbial translocation and exposure to pathogen-associated molecular patterns (PAMPs) that activate pattern recognition receptors on dendritic cells, amplifying Th17 responses. Cross-reactive epitopes between Streptococcus pyogenes, Staphylococcus aureus, and host joint antigens have been implicated in triggering disease flares.

• Skin-joint axis and psoriasis-arthritis transition: The pathogenic mechanisms are shared between skin and joints; IL-23 and TNF-α drive both psoriasiform inflammation in epidermis and synovitis in joints. The transition from isolated psoriasis to PsA involves accumulation of autoreactive T cells and epitope spreading. Keratinocytes and skin-resident dendritic cells produce IL-23 in response to injury or infection, creating a reservoir of pathogenic T cells that can disseminate systemically and seed joints.

• Bone and structural damage: Osteoclastogenesis in PsA is driven by increased RANKL, TNF-α, and IL-17 in the synovial microenvironment. Paradoxically, PsA exhibits both bone erosion and new bone formation (osteophytes, syndesmophytes in axial disease), a feature partly explained by IL-17–mediated activation of osteoblasts through OSX and Runx2 transcription factors, alongside osteoclast activation. This bone anabolism contrasts with purely erosive diseases and suggests distinct immune mechanisms in PsA.

• HLA-B27 positivity: Present in 60–70% of patients with PsA and strongly associated with axial spine involvement (spondylitis, sacroiliitis). HLA-B27 is the single strongest genetic risk factor and is a cornerstone of spondyloarthritis classification. Patients with HLA-B27 typically have earlier age of arthritis onset and more severe structural damage. However, HLA-B27 positivity is neither necessary nor sufficient for disease development, illustrating the polygenic and multifactorial nature of PsA.

• HLA-Cw6 and HLA-B39 alleles: HLA-Cw6 association is particularly strong with cutaneous psoriasis and is linked to earlier onset of skin disease, which often precedes arthritis development. These alleles contribute to disease heterogeneity and may predispose to specific clinical phenotypes (e.g., polyarticular vs. oligoarticular).

• Prior or concurrent psoriasis: This is the single most consistent environmental/clinical risk factor. Approximately 6–42% of psoriasis patients develop arthritis, with risk increasing with psoriasis duration, severity, and scalp involvement. PsA can precede skin manifestations in 10% of cases, but concurrent cutaneous psoriasis substantially increases likelihood of diagnosis. Psoriasis severity correlates with arthritis risk and severity.

• Environmental triggers: Mechanical trauma (Koebner phenomenon) to skin and joints may precipitate disease onset or flare. Streptococcal pharyngitis has been epidemiologically linked to PsA flares. HIV infection, particularly during immune reconstitution inflammatory syndrome (IRIS), can unmask or exacerbate PsA. Smoking is an independent risk factor for disease development and severity, particularly in RF-negative individuals.

• Family history and genetic clustering: Approximately 40% of PsA patients report a family history of psoriasis or arthritis, indicating strong heritability. Twin studies suggest 30–50% genetic contribution to disease susceptibility. Non-HLA genetic loci (IL23R, IL12B, TNF, IL10, TRAF3IP2, CARD9) have been identified through genome-wide association studies (GWAS) and account for additional disease risk beyond HLA.

• Obesity: Elevated BMI is associated with increased risk of PsA development and may act as a proinflammatory state that promotes disease progression. Adipose tissue produces TNF-α, IL-6, and leptin, amplifying systemic inflammation.

• Medications: Beta-blockers and lithium are associated with worsening or triggering psoriasis and may increase arthritis risk indirectly. Withdrawal of systemic corticosteroids has historically precipitated PsA onset.

• Peripheral polyarticular arthritis (most common, ~65% of patients): Insidious onset of symmetrical polyarticular joint pain and swelling, most commonly affecting the PIP joints of the hands, MCPs, wrists, knees, and ankles. Morning stiffness lasting >1 hour is characteristic and reflects overnight accumulation of synovial fluid and cellular infiltration. Joints appear warm, swollen, and erythematous with restricted range of motion. This pattern resembles rheumatoid arthritis but occurs in the absence of RF and anti-CCP antibodies; radiographs may show erosions indistinguishable from RA, but the distribution pattern differs (DIP involvement in PsA vs. MCP/PIP sparing in RA).

• Oligoarticular arthritis (~25% of patients): Asymmetrical involvement of typically fewer than five joints, often large weight-bearing joints (knees, ankles) or small hand joints. This subset tends toward less severe systemic disease and may progress to polyarticular involvement. Oligoarticular disease is the earliest clinical presentation in many patients and may persist for years.

• Spondylitis and axial involvement (~25% of patients, often overlap with peripheral disease): Inflammatory back pain with morning stiffness lasting >30 minutes, improvement with activity (distinguishing from mechanical back pain), and nighttime pain causing awakening. Examination reveals limited lumbar spine flexion (modified Schober test <4 cm) and reduced cervical spine mobility. Sacroiliitis occurs in 20–30% of patients and is frequently asymptomatic on imaging despite HLA-B27 positivity. Syndesmophyte formation leads to bamboo spine appearance on radiographs, fusion of vertebral bodies, and potential atlantoaxial instability requiring assessment before neck manipulation.

• Dactylitis ("sausage digit"): Diffuse swelling of an entire finger or toe from simultaneous synovitis and tenosynovitis, producing a characteristic spindle-shaped appearance. Dactylitis is more common in PsA than in RA (~40% of PsA patients) and correlates with more severe radiographic damage and need for biologic therapy. Dactylitis indicates active disease and higher burden of enthesopathy.

• Enthesitis: Inflammatory involvement of tendon and ligament insertion sites, manifesting as localized pain and tenderness at the Achilles tendon insertion, plantar fascia origin, and patellar tendon. Achilles enthesitis is particularly common and may precede or occur independently of articular inflammation. Pain is worst with passive stretch and is often more functionally limiting than articular swelling. Ultrasound reveals hypoechoic swelling at the enthesis with increased power Doppler signal.

• Cutaneous psoriasis: Present in >85% of PsA patients at diagnosis and in >95% during lifetime disease course. Manifestations include plaque psoriasis (erythematous, scaly patches on extensor surfaces, scalp, nails), guttate psoriasis (small raindrop-like lesions following streptococcal infection), and inverse psoriasis (intertriginous areas). Nail involvement (onycholysis, pitting, subungual hyperkeratosis, nail dystrophy) occurs in 70–80% of PsA patients and correlates with DIP joint involvement and more aggressive arthritis. Pustular psoriasis is associated with particularly severe arthritis.

• Eye involvement: Anterior uveitis occurs in 7–26% of patients, often HLA-B27 positive individuals, presenting with eye pain, photophobia, and blurred vision. Uveitis can be the presenting manifestation and requires urgent ophthalmology referral. Conjunctivitis and episcleritis are also reported.

• Systemic manifestations: Low-grade fever, fatigue, and constitutional symptoms are common. Unlike RA, systemic nodules are rare in PsA. Elevated inflammatory markers (CRP, ESR) correlate with disease activity but may be normal in 20–30% of active PsA patients, particularly those with primarily axial or oligoarticular disease.

• Mutilating arthritis (rare, <5%): Severe, rapidly progressive osteolytic disease causing gross joint destruction and loss of bone stock, particularly in fingers and toes. This occurs predominantly in early-onset, RF/anti-CCP-negative PsA and carries high risk of permanent disability without aggressive early intervention. Radiographs show "pencil-in-cup" deformity, telescoping digits, and total resorption of bone.

• PsA-associated comorbidities: Metabolic syndrome, obesity, cardiovascular disease, and reduced life expectancy are significantly elevated. Inflammatory markers predict cardiovascular events, necessitating aggressive risk factor modification.

• CASPAR Criteria (sensitivity 98.7%, specificity 96.3% vs. non-PsA inflammatory arthropathies): Requires presence of inflammatory articular disease (joint swelling, tenderness, or both) plus ≥3 points from the following: (1) psoriasis evidence—current psoriasis (2 points), personal history of psoriasis (1 point), family history of psoriasis (1 point); (2) nail involvement—onycholysis, pitting, hyperkeratosis (1 point); (3) negative RF (1 point); (4) dactylitis—current (2 points) or history of (1 point); (5) radiographic evidence of juxta-articular new bone formation (1 point). CASPAR is the gold standard for diagnosis and is superior to older classification criteria (Moll and Wright, Vasey and Espinoza).

• Serologic testing: Rheumatoid factor (RF) and anti-CCP antibodies are negative in the vast majority of PsA patients; seropositivity occurs in ~10% and represents "overlap" disease with overlap features of RA. HLA-B27 testing is not required for diagnosis but is positive in 60–70% of patients and strongly predicts axial involvement; positive HLA-B27 should raise suspicion for spondylitis even in asymptomatic patients. ANA testing is negative or low-titer in PsA and presence of significant ANA titers or specific extractable nuclear antibodies should prompt consideration of systemic lupus erythematosus (SLE) or other connective tissue diseases. Inflammatory markers (CRP, ESR) are typically elevated during active disease but may be normal in 20–30% of patients, particularly with oligoarticular or purely axial involvement; their absence does not exclude PsA.

• Acute phase reactants: Elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) correlate with disease activity and radiographic progression but lack sensitivity for diagnosis. CRP is more specific for active joint inflammation than ESR. Serial CRP monitoring helps assess treatment response; normalization suggests adequate disease control.

• Plain radiography: Early changes include soft tissue swelling and periarticular osteopenia. Progressive findings include joint space narrowing, marginal erosions (often with "bony proliferation" at erosion margins, a distinctive feature), and periosteal new bone formation. DIP joint involvement is characteristic of PsA and relatively uncommon in RA, occurring in ~40% of PsA patients. Pencil-in-cup deformity indicates severe erosive disease. Axial spine radiographs may show flowing syndesmophytes (less delicate than in ankylosing spondylitis), asymmetrical sacroiliitis, and bamboo spine in advanced disease. Early radiographic changes may be absent in first 6–12 months, necessitating clinical judgment.

• Magnetic resonance imaging (MRI): More sensitive than radiographs for detecting early erosions, synovitis, and bone marrow edema. MRI of sacroiliac joints demonstrates asymmetrical involvement with inflammatory signal changes before radiographic changes appear. MRI can reveal enthesitis and tenosynovitis not visible on radiographs or ultrasound. Ultrasound (US) is increasingly used for detailed assessment of synovitis, power Doppler signal (indicating active inflammation), and enthesitis. US is more accessible than MRI for serial monitoring and correlates with clinical activity.

• Sacroiliitis assessment: Plain radiographs may appear normal early in disease; **HLA-

Immediate/supportive measures

• Acute monoarticular flare: exclude septic arthritis by arthrocentesis before assuming a PsA flare; intra-articular glucocorticoid injection is acceptable once infection is excluded.
• Nonpharmacologic: physical therapy, smoking cessation, and weight loss — obesity blunts response to TNF inhibitors and worsens skin disease. GRAPPA and the ACR/NPF both emphasize aggressive cardiovascular risk factor management.

First-line pharmacotherapy

• NSAIDs (e.g., naproxen): reasonable monotherapy only for mild peripheral arthritis or enthesitis; they do not prevent radiographic progression.
• TNF inhibitors (e.g., adalimumab, infliximab, etanercept): ACR/NPF 2018 conditionally recommends a TNF inhibitor over methotrexate as initial therapy in treatment-naive patients with active PsA, because TNF blockade retards erosive damage. GRAPPA permits a conventional synthetic DMARD first in mild disease or limited access.
• Methotrexate (csDMARD): still widely used first in peripheral polyarthritis with prominent skin disease; requires folic acid supplementation. It is ineffective for axial disease and has weak evidence for enthesitis.

Escalation/second line

• IL-17 inhibitors (secukinumab, ixekizumab) and IL-23/IL-12-23 inhibitors (guselkumab, ustekinumab) — favored when skin disease is severe or after TNF inhibitor failure.
• JAK inhibitors (tofacitinib, upadacitinib) — effective across domains but carry an FDA boxed warning for major cardiovascular events, malignancy, thrombosis, and mortality; reserve for inadequate response to biologics.
• Apremilast (PDE4 inhibitor) — oral option for mild/moderate disease; side effects include diarrhea, weight loss, and depression.
• Axial disease: NSAIDs, then TNF or IL-17 inhibitor (not methotrexate).

Contraindications/cautions

• Live vaccines during biologic therapy; screen for latent TB and hepatitis B before TNF inhibitors.
• TNF inhibitors in advanced heart failure or demyelinating disease; IL-17 inhibitors in inflammatory bowel disease (may exacerbate it).
• Methotrexate and leflunomide are teratogenic and contraindicated in pregnancy.
• Avoid systemic glucocorticoids where possible — tapering can precipitate pustular psoriasis.

Disease-related

• Arthritis mutilans: osteoclast-driven osteolysis with resorption of phalanges; signaled by telescoping digits ("opera-glass hand") and pencil-in-cup radiographic change. Irreversible — the reason for early biologic therapy.
• Axial ankylosis and atlantoaxial instability: IL-17/IL-23-driven new bone formation causes syndesmophytes and spinal fusion; a fused, osteoporotic spine fractures with minor trauma. Emergency: new neck or back pain after a fall in a patient with axial PsA warrants CT and spinal precautions, as unstable fracture with cord injury is the concern.
• Acute anterior uveitis: HLA-B27-associated intraocular inflammation. Emergency — unilateral painful red eye with photophobia and ciliary flush requires same-day slit-lamp examination; untreated it causes synechiae and vision loss.
• Accelerated atherosclerosis: chronic systemic IL-6/TNF-α exposure plus metabolic syndrome; signaled by premature MI/stroke. This is the leading cause of excess mortality in PsA.
• Inflammatory bowel disease: shared IL-23/Th17 axis; suspect with chronic diarrhea, blood per rectum, or iron-deficiency anemia.
• Secondary (AA) amyloidosis: rare, from sustained serum amyloid A elevation; signaled by new nephrotic-range proteinuria.

Treatment-related

• Reactivation tuberculosis with TNF inhibitors: TNF-α maintains granuloma integrity, so blockade permits dissemination. Emergency — fever, weight loss, and miliary infiltrates; screen with IGRA/PPD plus chest x-ray before starting therapy.
• Hepatitis B reactivation: loss of immune containment of cccDNA; rising transaminases and HBV DNA can progress to fulminant hepatitis.
• Serious bacterial infection/sepsis with any biologic; mucocutaneous candidiasis specifically with IL-17 inhibitors, since IL-17 mediates antifungal mucosal defense.
• Methotrexate toxicity: hepatic fibrosis, oral ulcers, and myelosuppression (worsened by trimethoprim-sulfamethoxazole or renal impairment); pancytopenia with mucositis is an emergency treated with leucovorin. Methotrexate pneumonitis presents as subacute dyspnea with a diffuse interstitial pattern.
• JAK inhibitors: venous thromboembolism, MACE, and herpes zoster reactivation; acute dyspnea/pleuritic pain warrants urgent PE evaluation.
• Glucocorticoid withdrawal: rebound generalized pustular psoriasis (von Zumbusch) with fever, sheets of sterile pustules, and hypovolemia — a dermatologic emergency.
• Demyelination and drug-induced lupus with TNF inhibitors; new optic neuritis or paresthesias mandates drug cessation and MRI.

• **The sausage digit is the giveaway**: uniform fusiform swelling of a whole finger or toe (dactylitis) plus scaly extensor plaques or nail pitting equals PsA until proven otherwise. Combined synovitis and tenosynovitis explains why the entire digit swells, not just the joint line.
• DIP disease plus nail changes travel together: the nail matrix and DIP extensor enthesis are anatomically continuous, so onycholysis, pitting, and subungual hyperkeratosis predict DIP arthritis. This DIP predilection is the single best clinical discriminator from rheumatoid arthritis.
• Seronegative by definition: RF and anti-CCP are negative. A stem that gives a positive anti-CCP with symmetric MCP/PIP synovitis and ulnar deviation wants rheumatoid arthritis, not PsA.
• Radiographic buzzword: pencil-in-cup deformity with adjacent new bone formation. Erosion plus proliferation is uniquely psoriatic — purely erosive disease without bony proliferation suggests RA.
• Single best next step, painful red eye: urgent slit-lamp examination for HLA-B27-associated acute anterior uveitis. Do not order a topical steroid or antibiotic empirically from the stem.
• Single best next step, before a TNF inhibitor: latent TB screening (IGRA or PPD) with chest x-ray, plus hepatitis B serologies — this is the most commonly tested pre-biologic step.
• The association examiners love: IL-17 inhibitors (secukinumab, ixekizumab) may unmask or worsen inflammatory bowel disease; in a patient with PsA and Crohn disease, choose a monoclonal TNF inhibitor (adalimumab, infliximab) instead. Etanercept is also the weakest TNF agent for uveitis and IBD.
• Common distractor — systemic steroids: they transiently help joints but withdrawal can trigger generalized pustular psoriasis. Methotrexate is another trap when the vignette emphasizes axial back pain — it does not work for axial disease; a TNF or IL-17 inhibitor does.
• Do not forget cardiovascular risk: PsA is a chronic inflammatory state with excess MI and stroke; statin and blood pressure management are part of the answer, not an afterthought.